Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
Rhea-AI Summary
Acurx Pharmaceuticals (NASDAQ: ACXP) will discuss its first quarter 2026 financial results on Tuesday, May 12, 2026 at 8:00 a.m. ET before U.S. markets open. David P. Luci, president and CEO, and Robert G. Shawah, CFO, will host a conference call and provide a business update. Participant dial-in details and international toll-free numbers are available; U.S. access ID is 13760162.
Positive
- None.
Negative
- None.
News Market Reaction – ACXP
On the day this news was published, ACXP declined 0.84%, reflecting a mild negative market reaction. Argus tracked a trough of -4.8% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $70K from the company's valuation, bringing the market cap to $8.22M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Conferences,earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 16 | Earnings call notice | Neutral | +0.5% | Announced March 13, 2026 full-year and Q4 2025 results call. |
| Oct 27 | Earnings call notice | Neutral | +1.4% | Scheduled Q3 2025 results call for November 12, 2025 at 8 a.m. ET. |
| Jul 24 | Earnings call notice | Neutral | -1.1% | Set August 12, 2025 Q2 2025 results and business update call. |
| Apr 30 | Earnings call notice | Neutral | +2.4% | Announced May 13, 2025 Q1 2025 financial results conference call. |
| Feb 28 | Earnings call notice | Neutral | +3.4% | Planned March 18, 2025 call for Q4 and full-year 2024 results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Scheduling earnings/business update calls has historically led to modest, mixed price moves, with an average reaction of about 1.32% across past similar announcements.
Over the past year, Acurx has repeatedly issued “conference call and business update” notices tied to quarterly or annual results, typically scheduled at 8:00 a.m. ET before the market open. These events, hosted by the CEO and CFO, previously produced small positive or negative moves, averaging about 1.32%. Today’s Q1 2026 call notice follows that same pattern and fits into a regular cadence of financial communication rather than a new operational milestone.
AI-generated analysis. How Rhea-AI works. Not financial advice.
David P. Luci, President and Chief Executive Officer, and Robert G. Shawah, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:
Date: | Tuesday, May 12, 2026 |
Time: | 8:00 a.m. ET |
Toll free ( | 877-790-1503 Access ID: 13760162 |
Click here for participant International Toll-Free access numbers
About Ibezapolstat
Ibezapolstat is the Company's lead antibiotic candidate preparing for advancement into international Phase 3 clinical trials to treat patients with acute C. difficile Infection (CDI) and it is also preparing for a ground-breaking clinical trial targeting the prevention of recurrent CDI (rCDI). If successful, ibezapolstat will change the treatment paradigm for CDI and rCDI by providing one therapy for the full spectrum of CDI and rCDI from first occurrence to multiply recurrent episodes.
Ibezapolstat is a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS®) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors under development by Acurx to treat bacterial infections. Ibezapolstat's unique spectrum of activity, which includes C. difficile but spares other Firmicutes and the important Actinobacteria phyla, appears to contribute to the maintenance of a healthy gut microbiome. As previously announced, the Company has received final EMA and FDA agreement for our ibezapolstat pivotal Phase 3 trials in CDI. Their advice included and confirmed the non-inferiority study design elements, the patient population, primary and secondary endpoints, and size of the registration safety database. Acurx also now has a clear international roadmap for conduct of its Phase 3 program in CDI and, if successful, requirements for US NDA submission and EU Marketing Authorization.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials as soon as possible. The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether ibezapolstat will benefit from the QIDP designation; whether ibezapolstat will advance through the clinical trial process on a timely basis; whether the results of the clinical trials of ibezapolstat will warrant the submission of applications for marketing approval, and if so, whether ibezapolstat will receive approval from the FDA or equivalent foreign regulatory agencies where approval is sought; whether, if ibezapolstat obtains approval, it will be successfully distributed and marketed; and other risks and uncertainties described in the Company's annual report filed with the Securities and Exchange Commission on Form 10-K for the year ended December 31, 2025, and in the Company's subsequent filings with the Securities and Exchange Commission. Such forward- looking statements speak only as of the date of this press release, and Acurx disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances after the date of such statements, except as may be required by law.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & CEO
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-discuss-first-quarter-2026-financial-results-on-may-12-2026-conference-call-and-provide-business-update-302745436.html
SOURCE Acurx Pharmaceuticals, Inc.